Tirzepatide is the same
active ingridients in
Mounjaro & Zepbound
Tirzepatide is once-weekly injectable dual glucagon-like peptide 1 (GLP-1) receptor and glucose-dependent
insulinotropic polypeptide (GIP) receptor agonist.
It works by increasing insulin production and lowers
glucagon secretion as well as targets areas in the brain that regulate appetite and food intake.
A small change in the molecule allows the drug to last weeks in our bodies rather than the natural version our bodies make, which
lasts minutes.
How Does Tirzepatide Work?
● Delays how quickly our stomachs digest food. Leading to a feeling of fullness and satisfaction with smaller meal sizes.
● Slows intestinal motility so you will feel fuller longer after meals.
● Dual action receptor allows for lower blood sugars, in part by reducing the production of sugar in the liver.
● Stimulates insulin secretion by the pancreas.
● GIP increases energy expenditure, resulting in weight loss reductions
Side Effects
The most common side effects include nausea and constipation. Patients also report acid reflux, stomach pain, vomiting, and diarrhea. The risk of serious side effects increases in patients with hypoglycemia, kidney problems, and risk of allergic reactions.
**This medication is not insulin and should not be used if you have type 1 diabetes or if you develop diabetic ketoacidosis. Tirzepatide should not be used with any other GLP-1 medications.
Benefits of Semaglutide
- Decreased appetite and cravings
- Weight loss
- A1C reduction
- Improved cardiometabolic measures
Semaglutide
Weekly Injection
Active ingredient in Ozempic & Wegovy
15% body weight reduction
GLP-1 receptor agonist
FDA approved for Type 2 diabetes (2017 - Ozempic) & Weight loss (2021 - Wegovy)
Most common side effects:
nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain
Semaglutide
DOSING CHART
DOSE | SCHEDULE |
0.25 MG | WEEK 1-4 |
0.50 MG | WEEK 5-8 |
1.0 MG | WEEK 9-12 |
1.75 MG | WEEK 13-16 |
2.50 MG | WEEK 17-20 |
Tirzepatide
Weekly Injection
Active ingredient in Mounjaro & Zepbound
22% body weight reduction
Dual GLP-1 & GIP receptor agonist
FDA approved for Type 2 diabetes (2022 - Mounjaro) & Weight loss (2023 Zepbound)
Most common side effects:
nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain
Tirzepatide
DOSING CHART
DOSE | SCHEDULE |
2.5 MG | WEEK 1-4 |
5.0 MG | WEEK 5-8 |
7.5 MG | WEEK 9-12 |
10.5MG | WEEK 13-16 |
12.5 MG | WEEK 17-20 |
Start losing weight in 3 Easy Steps
Book A Free Consultation
Complete all medical forms and consents
Complete Visit &
Receive your medications
Every prescription is formulated at the discretion of the medical provider and may not be appropriate for all individuals.
Let's discuss
more
8127 Mulberry Ave, #108
Fontana, CA 92335
Call/Text: (909) 582-4665
Follow Us
Restore Youth Weightloss & Wellness is a patient management platform that employs medical providers and practitioners. Medical services are rendered by independent providers and may vary dependent on assessment and discretion. The information on this website is for educational purposes only and is not a replacement for professional medical advice, diagnosis, or treatment. If you have health-related questions or concerns, please consult your doctor. This website is an advertisement for services, which may include medications that are commonly use.
*Disclaimer: FDA-approved medications like Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™, while Mounjaro™ and Zepbound are a product of Eli Lilly and Company™. Restore YOUth is not associated with or endorsed by these companies or their products. We do not supply these medications. Individuals interested in these products should consult with their licensed healthcare provider or pharmacist.